|
Market Closed -
NSE India S.E.
07:05:08 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 1,832.60 INR | -4.21% |
|
-4.32% | +29.16% |
| 08-14 | Ipca Laboratories Limited, Q1 2027 Earnings Call, Aug 14, 2026 | |
| 08-13 | Ipca Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
Company Valuation: Ipca Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 270,385 | 205,589 | 313,934 | 381,038 | 406,231 | 464,938 | - | - |
| Change | - | -23.96% | 52.7% | 21.38% | 6.61% | 14.45% | - | - |
| Enterprise Value (EV) 1 | 275,070 | 201,870 | 325,349 | 391,231 | 408,673 | 454,288 | 444,982 | 432,795 |
| Change | - | -26.61% | 61.17% | 20.25% | 4.46% | 11.16% | -2.05% | -2.74% |
| P/E | 30.6x | 43.6x | 57.4x | 51.6x | 35.6x | 30.7x | 26.1x | 23.1x |
| PBR | 4.92x | 2.58x | 4.96x | 5.48x | 5.04x | 4.95x | 4.25x | 3.7x |
| PEG | - | -0.9x | 3.6x | 1.5x | 0.7x | 0.9x | 1.5x | 1.8x |
| Capitalization / Revenue | 4.64x | 3.29x | 4.07x | 4.26x | 4.21x | 4.23x | 3.79x | 3.43x |
| EV / Revenue | 4.72x | 3.23x | 4.22x | 4.38x | 4.24x | 4.13x | 3.63x | 3.19x |
| EV / EBITDA | 21x | 21.8x | 24.6x | 22.7x | 20.7x | 18x | 15.2x | 13.2x |
| EV / EBIT | 25.6x | 30.3x | 33.8x | 29.5x | 26.2x | 22.2x | 18.9x | 16.1x |
| EV / FCF | 72.9x | 64.8x | 60.9x | 71.7x | 83.5x | 58x | 36.8x | 27.6x |
| FCF Yield | 1.37% | 1.54% | 1.64% | 1.4% | 1.2% | 1.72% | 2.71% | 3.63% |
| Dividend per Share 2 | 8 | 4 | 4 | 2 | 6 | 5.769 | 6.185 | 7.114 |
| Rate of return | 0.75% | 0.49% | 0.32% | 0.13% | 0.37% | 0.31% | 0.34% | 0.39% |
| EPS 2 | 34.85 | 18.58 | 21.57 | 29.08 | 44.98 | 59.78 | 70.28 | 79.39 |
| Distribution rate | 23% | 21.5% | 18.5% | 6.88% | 13.3% | 9.65% | 8.8% | 8.96% |
| Net sales 1 | 58,298 | 62,443 | 77,050 | 89,396 | 96,463 | 109,899 | 122,709 | 135,578 |
| EBITDA 1 | 13,073 | 9,268 | 13,212 | 17,261 | 19,786 | 25,214 | 29,210 | 32,846 |
| EBIT 1 | 10,748 | 6,652 | 9,639 | 13,283 | 15,604 | 20,422 | 23,508 | 26,962 |
| Net income 1 | 8,841 | 4,713 | 5,474 | 7,377 | 11,411 | 15,122 | 17,896 | 20,251 |
| Net Debt 1 | 4,685 | -3,720 | 11,415 | 10,193 | 2,442 | -10,650 | -19,956 | -32,144 |
| Reference price 2 | 1,065.75 | 810.35 | 1,237.40 | 1,501.90 | 1,601.20 | 1,832.60 | 1,832.60 | 1,832.60 |
| Nbr of stocks (in thousands) | 253,704 | 253,704 | 253,704 | 253,704 | 253,704 | 253,704 | - | - |
| Announcement Date | 5/24/22 | 5/29/23 | 5/29/24 | 5/29/25 | 5/29/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 30.66x | 4.13x | 18.02x | 0.31% | 4.9B | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 29.21x | 6.67x | 18.35x | 1.97% | 394.58B | |
| Weighted average by Cap. | 34.72x | 8.20x | 20.04x | 1.83% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- IPCALAB Stock
- Valuation Ipca Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
